Latest Chemomab Therapeutics News & Updates

See the latest news and media coverage for Chemomab. We track all announcements, press releases, and industry mentions in real time, all in one place.

Chemomab Therapeutics (Chemomab)

Clinical-stage biotechnology company developing fibro-inflammatory therapeutics

chemomab.com

Headquarters: Tel Aviv, Israel
Founded year: 2011
Company type: Public company
Number of employees: 20–50

Last updated Today

Latest news about Chemomab Therapeutics (Chemomab)

In short: Chemomab advanced its lead candidate nebokitug toward Phase 3 trials for PSC while managing financial risks and reporting a Q1 2026 net loss.

Company announcements

May 14 Chemomab

Chemomab announced first quarter 2026 financial results

The company reported net loss of $1.8 million and provided updates on nebokitug clinical progress.

May 5 Chemomab

Chemomab announces nebokitug proteomic study results

Dr. Parvez Mantry presented dose-dependent reductions in inflammatory signatures at Digestive Disease Week. Data suggest benefits for PSC patients with IBD. Q1 2026 results release on May 14.

March 19 Chemomab

Chemomab announces 2025 year-end financial results

Reports $10.4M cash, reduced R&D expenses, net loss of $9.0M. Highlights FDA alignment on Phase 3 PSC trial for nebokitug and strategic partner discussions.

February 27 Chemomab

Chemomab develops treatments for rare diseases

Nebokitug prepares for Phase 3 trial in primary sclerosing cholangitis and is Phase 2-ready for systemic sclerosis.

Media coverage

June 2 TipRanks

Top Executive’s Sudden Stock Move Sends Chemomab Investors Scrambling - TipRanks.com

New insider activity at Chemomab Therapeutics ( ($CMMB) ) has taken place on June 1, 2026. Chemomab Therapeutics has reported an insider transaction by its...

May 14 Markets Insider

Chemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update

New Clinical and Translational Data Presented at Major Medical Meetings Further Confirms the Disease-Modifying Potential of Nebokitug in Primary ...

March 23 Stock Titan

Chemomab Therapeutics (CMMB) flags going-concern risk and reliance on nebokitug

Chemomab Therapeutics, a clinical-stage Israeli biopharma company, filed its annual report outlining its business, key risks and financial position. The company focuses on nebokitug (CM-101...

March 21 The Globe and Mail

Chemomab Therapeutics Sets April 28, 2026 Shareholder Meeting to Vote on Capital Increase and Governance Matters

Detailed price information for Chemomab Therapeutics Ltd ADR (CMMB-Q) from The Globe and Mail including charting and trades.

Never miss news about Chemomab

Track Chemomab and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Chemomab competitors & trending companies

Browse news for competitors to Chemomab and other trending companies.